HYUNDAI BIOLAND Statistics
Total Valuation
HYUNDAI BIOLAND has a market cap or net worth of KRW 133.95 billion. The enterprise value is 136.00 billion.
| Market Cap | 133.95B | 
| Enterprise Value | 136.00B | 
Important Dates
The last earnings date was Monday, August 4, 2025.
| Earnings Date | Aug 4, 2025 | 
| Ex-Dividend Date | Dec 27, 2024 | 
Share Statistics
HYUNDAI BIOLAND has 30.00 million shares outstanding. The number of shares has increased by 14.28% in one year.
| Current Share Class | 30.00M | 
| Shares Outstanding | 30.00M | 
| Shares Change (YoY) | +14.28% | 
| Shares Change (QoQ) | n/a | 
| Owned by Insiders (%) | n/a | 
| Owned by Institutions (%) | 0.75% | 
| Float | 19.50M | 
Valuation Ratios
The trailing PE ratio is 10.72 and the forward PE ratio is 7.32.
| PE Ratio | 10.72 | 
| Forward PE | 7.32 | 
| PS Ratio | 1.06 | 
| PB Ratio | 0.99 | 
| P/TBV Ratio | 1.02 | 
| P/FCF Ratio | 53.00 | 
| P/OCF Ratio | 19.19 | 
| PEG Ratio | n/a | 
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.34, with an EV/FCF ratio of 53.81.
| EV / Earnings | -33.77 | 
| EV / Sales | 1.08 | 
| EV / EBITDA | 6.34 | 
| EV / EBIT | 8.68 | 
| EV / FCF | 53.81 | 
Financial Position
The company has a current ratio of 3.86, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.86 | 
| Quick Ratio | 1.48 | 
| Debt / Equity | 0.08 | 
| Debt / EBITDA | 0.50 | 
| Debt / FCF | 4.21 | 
| Interest Coverage | 30.52 | 
Financial Efficiency
Return on equity (ROE) is 9.02% and return on invested capital (ROIC) is 6.09%.
| Return on Equity (ROE) | 9.02% | 
| Return on Assets (ROA) | 5.61% | 
| Return on Invested Capital (ROIC) | 6.09% | 
| Return on Capital Employed (ROCE) | 11.53% | 
| Revenue Per Employee | 370.02M | 
| Profits Per Employee | -11.81M | 
| Employee Count | 341 | 
| Asset Turnover | 0.72 | 
| Inventory Turnover | 1.50 | 
Taxes
In the past 12 months, HYUNDAI BIOLAND has paid 1.44 billion in taxes.
| Income Tax | 1.44B | 
| Effective Tax Rate | 10.34% | 
Stock Price Statistics
The stock price has decreased by -13.63% in the last 52 weeks. The beta is 0.88, so HYUNDAI BIOLAND's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 | 
| 52-Week Price Change | -13.63% | 
| 50-Day Moving Average | 4,639.50 | 
| 200-Day Moving Average | 4,669.38 | 
| Relative Strength Index (RSI) | 40.30 | 
| Average Volume (20 Days) | 104,066 | 
Short Selling Information
| Short Interest | n/a | 
| Short Previous Month | n/a | 
| Short % of Shares Out | n/a | 
| Short % of Float | n/a | 
| Short Ratio (days to cover) | n/a | 
Income Statement
In the last 12 months, HYUNDAI BIOLAND had revenue of KRW 126.18 billion and -4.03 billion in losses. Loss per share was -134.25.
| Revenue | 126.18B | 
| Gross Profit | 55.07B | 
| Operating Income | 15.67B | 
| Pretax Income | 13.94B | 
| Net Income | -4.03B | 
| EBITDA | 21.44B | 
| EBIT | 15.67B | 
| Loss Per Share | -134.25 | 
Balance Sheet
The company has 8.59 billion in cash and 10.64 billion in debt, giving a net cash position of -2.05 billion or -68.18 per share.
| Cash & Cash Equivalents | 8.59B | 
| Total Debt | 10.64B | 
| Net Cash | -2.05B | 
| Net Cash Per Share | -68.18 | 
| Equity (Book Value) | 134.65B | 
| Book Value Per Share | 4,488.31 | 
| Working Capital | 60.39B | 
Cash Flow
In the last 12 months, operating cash flow was 6.98 billion and capital expenditures -4.45 billion, giving a free cash flow of 2.53 billion.
| Operating Cash Flow | 6.98B | 
| Capital Expenditures | -4.45B | 
| Free Cash Flow | 2.53B | 
| FCF Per Share | 84.25 | 
Margins
Gross margin is 43.65%, with operating and profit margins of 12.42% and -3.19%.
| Gross Margin | 43.65% | 
| Operating Margin | 12.42% | 
| Pretax Margin | 11.05% | 
| Profit Margin | -3.19% | 
| EBITDA Margin | 16.99% | 
| EBIT Margin | 12.42% | 
| FCF Margin | 2.00% | 
Dividends & Yields
This stock pays an annual dividend of 35.00, which amounts to a dividend yield of 0.79%.
| Dividend Per Share | 35.00 | 
| Dividend Yield | 0.79% | 
| Dividend Growth (YoY) | 100.00% | 
| Years of Dividend Growth | 1 | 
| Payout Ratio | n/a | 
| Buyback Yield | -14.28% | 
| Shareholder Yield | -13.49% | 
| Earnings Yield | -3.01% | 
| FCF Yield | 1.89% | 
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
The last stock split was on May 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | May 17, 2024 | 
| Split Type | Forward | 
| Split Ratio | 2 | 
Scores
HYUNDAI BIOLAND has an Altman Z-Score of 6.42 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.42 | 
| Piotroski F-Score | 5 |